Our team has deep expertise across clinical and imaging disciplines, paradigm-shifting technology, and management/investor experience. Together, with our exceptional staff, we are now redefining how technology and medicine can work together to solve neurovascular disorders in ways never before possible.
Jim has 40+ years of experience and deep expertise bringing advanced technologies to market, providing leadership across the organization while engaging and partnering with regulators worldwide. Jim’s exposure as a leader in the medical device consulting industry allows him to leverage best practices from 50+ companies to accelerate regulatory approvals worldwide and maintain compliance with QMS regulations. Jim has worked in highly controlled regulatory environments to help deliver lung cancer markers for CeMines, Inc., an IVD company; led development of personalization technologies at Intel Architecture Labs; and integrated worldwide product engineering teams at Gambro. Additionally, his engineering background in high-speed signal processing for space and military applications allows for a keen understanding of the engineering process and its intersection with regulatory.
Jim also teaches and mentors university students and professionals in design controls, risk management, and V&V strategies worldwide, and holds patents related to usability, safety, and predictive maintenance concepts for medical devices.
He earned an MBA from Colorado State University and a BS in computer science from Radford University. Jim is a veteran of the U.S. Navy.
Amit is a senior healthcare and technology leader, heralded for driving transformative AI strategy across technology platforms for medical imaging and technology giants.
Most recently, Amit was a GE Officer and Chief Digital Officer for GE Healthcare, responsible for leading the company’s digital and AI strategy. Amit oversaw GE Healthcare’s complete digital portfolio, including Enterprise Imaging solutions, Clinical Command Centers and consulting solutions. With his global digital team, he enabled GE’s vision for precision health by creating the industry-leading Edison platform and its cloud, edge, device software infrastructure, data strategy, SaaS enablement, artificial intelligence, and analytics capabilities.
Prior to GE, Amit was with Cisco Systems, where he was the India Site Leader and Senior Vice President of Engineering for the Core Software Group, leading product development activities across routing, switching and wireless areas. Prior to working at Cisco Systems, Amit held leadership roles at Motorola, Tata Elxsi, Silicon Automation Systems and C-DOT.
As the Chief Innovation and Technology Officer at RapidAI, Amit oversees the R&D, Engineering and Technology organizations, driving the advancement of the RapidAI comprehensive AI and Workflow Platform for neurovascular and vascular disease care.
Amit has a master’s degree in electronics and communication from the Indian Institute of Science.
Matus has more than 20 years of experience in clinical, industrial, and academic fields, including expertise in medical software development, 2D- and 3D-image processing algorithms, and MRI and CT imaging. For nearly 15 years, he has been working on developing the Rapid® platform with team members, most recently serving as vice president of research and development at RapidAI. He led the development of the software for advanced brain imaging, working with a team of engineers on the development of algorithms, implementation and testing, customer installations, trial data collection, and more. During his post-doctoral work at Stanford, he worked with Greg Albers and Roland Bammer — who later co-founded what became RapidAI – on a large multi-center trial, DEFUSE2.
He completed post-doctoral study and research at Stanford University School of Medicine, holds a PhD in medical image processing from Vienna Technical University / Austrian Academy of Sciences in Vienna, Austria, and an M.Sc. from Slovak University of Technology in Bratislava, Slovakia.
Jim is a senior commercial leader in the medical device industry with over 20 years in leadership positions at Abbott, Johnson & Johnson, GE and most recently Terumo Aortic where he was Vice President of Sales and Marketing for North America. During his tenure with Terumo Aortic, the US division grew more than 10x in revenue through key growth and marketing strategies, new sales programs, and growth-based compensation plans. Throughout his time at Terumo, his responsibilities included Sales, Marketing, Training, Commercial Operations, National Accounts, Customer Service, Contracting, Business Development, as well as pricing strategies and building a strong commercial leadership team.
Prior to Terumo Aortic, Jim was with Abbott Vascular for 7 years including time as Area Vice President of Sales and US Director of Strategy and Execution. In these positions, Jim created a new strategy and channel for the division that resulted in over $500 million of sales growth in the US while transforming the division culture and reducing turnover significantly during his tenure.
A multi-disciplinary leader, Alex has more than 18 years of experience in software and healthcare. He is a proven leader focusing on generating new business and maximizing ROI. Before joining RapidAI, he held clinical, software, consulting, and leadership positions across pharmaceutical, life sciences, software, and technology industries including Baxter, Medtronic, Johnson & Johnson, Deloitte Consulting, Union Bank, Novartis, and Oracle. In his previous role, he managed a $20M+ company-wide program, spanning 12 key initiatives that delivered $30M+ in annual revenue and cost savings.
Alex holds a BA in economics, graduating with honors from the University of California, Irvine.
Greg has been instrumental in the development of the Rapid platform. Since 1992, he has served as the director and co-founder of the Stanford Stroke Center. His primary research focus is the diagnosis, management, and prevention of ischemic stroke. Working with his team, he has used advanced imaging technology to expand the treatment window for ischemic stroke and has been the principal investigator of all three DEFUSE studies. These NIH-funded research projects clarified the evolution of brain ischemia and led to extending the treatment window for stroke to 24 hours in 2018.
He is also the Coyote Foundation Professor of Neurology and Professor, by courtesy, of Neurosurgery at Stanford University Medical Center. A prolific and distinguished researcher, Greg has authored 450+ articles on cerebrovascular disease topics in peer-reviewed journals and serves as the Chairman of the Stroke Treatment Academic Industry Roundtable (STAIR).
A recipient of the American Heart Association’s David G. Sherman Award for Outstanding Contributions to Stroke Research in 2011, he received his MD from the University of California San Diego and completed his residency and stroke fellowship at Stanford University.
Roland was instrumental in helping develop early engineering/regulatory team members at RapidAI, and the business plan for core-lab services for two large industry-sponsored trials. A serial entrepreneur with 30+ years of experience developing academic/commercial software, he is Co-Director of the Stanford 3D Lab. Roland has published 240 peer-reviewed articles, holds 28 patents, and authored the seminal stroke and perfusion imaging textbook.
Since 2017, he has been Professor of Radiology and Director of Research Excellence in Neuroimaging at the University of Melbourne, and Director of Quantitative Neuroimaging at the Royal Melbourne Hospital, Australia. From 2001 to 2017, he served as a faculty member in the Department of Radiology (and, by courtesy, Neurology and the Neurosciences) at Stanford University.
He is also a Distinguished Investigator of the American Academy of Radiology Research, and a Senior Fellow of the International Society of Magnetic Resonance in Medicine (ISMRM). He holds a master's and Ph.D. in electrical engineering from Technische Universität Graz, an MBA from Deakin University, and a professorship degree in medical physics and biophysics from Karl-Franzens-Universität Graz.
Mark has more than 40 years of experience in investment management as well as extensive experience with leading global financial services firms, and co-founded the Stanford Stroke Advisory Board. He is managing director of Brandin & Associates, an investment management firm focused on equity and option growth strategies for high net worth clients. In addition to his board position at RapidAI, he is also a Limited Partner of Jana Partners, Lithium Technologies Inc., Life 360, Vasostitch, Niveus Medical Inc., Seraph Group, Simpson Interventions Inc., and A to Z Sports. His career has included executive vice president positions at Quick and Reilly, Inc., Charles Schwab & Co., Crocker National Bank, and positions at Shearson Lehman Hutton and First National Bank of Chicago.
Mark holds a degree in strategic marketing from Harvard University Graduate School of Business, an MBA from the University of Chicago, and a BA from Stanford University.
John has more than 20 years of operational, financial, and technical experience, including leadership positions at several global technology companies. He has been a General Partner at TCV, one of the largest growth equity firms, since 2002. Before joining TCV, he served as one of four CEOs in the Office of the Chairman at Lucent Technologies, President and CEO of International Network Services (acquired by Lucent), and Vice President and General Manager at Unisys Corporation. John began his business career after serving as a captain in the United States Army. In addition to his board position at RapidAI, he is on the board of directors of OneSource Virtual.
He holds a BS degree in engineering from the United States Military Academy at West Point and an MS degree in business policy from Columbia University.
Brendan Renehan is a Director at Vista Credit Partners (VCP) where he is responsible for the origination and evaluation of both private and public investments across VCP. Mr. Renehan is a board member of Rocket Lawyer and a board observer of AssureCare, Artsy and Certane.
Prior to joining Vista Credit Partners in 2018, Mr. Renehan worked at Ares Management in the Direct Lending division for four years, most recently as a Senior Associate. In addition to his credit responsibilities, Mr. Renehan also assisted in strategic endeavors of the firm, including portfolio acquisitions and fundraising activities. Before his time with Ares Management, Mr. Renehan was an Analyst at Bank of America Merrill Lynch in the Leveraged Finance division.
